8-K
JPMORGAN CHASE & CO (JPM)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): April 10, 2025
JPMorgan Chase & Co.
(Exact name of registrant as specified in its charter)
| Delaware | 1-5805 | 13-2624428 |
|---|---|---|
| (State or other jurisdiction<br> <br>of incorporation or organization) | (Commission<br> <br>File Number) | (I.R.S. employer<br> <br>identification no.) |
| 383 Madison Avenue, | ||
| --- | --- | |
| New York, New York | 10179 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (212) 270-6000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br> <br>Symbol(s) | Name of each exchange<br> <br>on which registered |
|---|---|---|
| Common stock | JPM | The New York Stock Exchange |
| Depositary Shares, each representing a one-four hundredth interest in a share of 5.75% Non-Cumulative Preferred Stock, Series DD | JPM PR D | The New York Stock Exchange |
| Depositary Shares, each representing a one-four hundredth interest in a share of 6.00% Non-Cumulative Preferred Stock, Series EE | JPM PR C | The New York Stock Exchange |
| Depositary Shares, each representing a one-four hundredth interest in a share of 4.75% Non-Cumulative Preferred Stock, Series GG | JPM PR J | The New York Stock Exchange |
| Depositary Shares, each representing a one-four hundredth interest in a share of 4.55% Non-Cumulative Preferred Stock, Series JJ | JPM PR K | The New York Stock Exchange |
| Depositary Shares, each representing a one-four hundredth interest in a share of 4.625% Non-Cumulative Preferred Stock, Series LL | JPM PR L | The New York Stock Exchange |
| Depositary Shares, each representing a one-four hundredth interest in a share of 4.20% Non-Cumulative Preferred Stock, Series MM | JPM PR M | The New York Stock Exchange |
| Guarantee of Callable Fixed Rate Notes due June 10, 2032 of JPMorgan Chase Financial Company LLC | JPM/32 | The New York Stock Exchange |
| Guarantee of Alerian MLP Index ETNs due January 28, 2044 of JPMorgan Chase Financial Company LLC | AMJB | NYSE Arca, Inc. |
| Guarantee of Inverse VIX Short-Term Futures ETNs due March 22, 2045 of JPMorgan Chase Financial Company LLC | VYLD | NYSE Arca, Inc. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01. | Other Events. |
|---|
On April 10, 2025, JPMorgan Chase & Co. (the “Company”) filed with the Securities and Exchange Commission a prospectus supplement dated April 10, 2025 (the “Prospectus Supplement”) related to the JPMorgan Chase & Co. Dividend Reinvestment Plan (the “Plan”). In connection with the filing of the Prospectus Supplement, Morgan, Lewis & Bockius LLP delivered a legality opinion, a copy of which is attached hereto as Exhibit 5.1, with respect to the shares of common stock, par value $1.00 per share, of the Company that may be offered and sold from time to time under the Plan.
| Item 9.01. | Financial Statements and Exhibits. |
|---|
(d) Exhibits
| 5.1 | Opinion of Morgan, Lewis & Bockius LLP. |
|---|---|
| 23.1 | Consent of Morgan, Lewis & Bockius LLP (included as part of Exhibit 5.1). |
| 101 | Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (eXtensible Business Reporting Language). |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| JPMORGAN CHASE & CO. | |
|---|---|
| (Registrant) | |
| By: | /s/ Stephen B. Grant |
| Name: | Stephen B. Grant |
| Title: | Assistant Corporate Secretary |
Dated: April 10, 2025
EX-5.1
Exhibit 5.1
April 10, 2025
JPMorgan Chase & Co.
383 Madison Avenue
New York, New York 10179
Re: 1,994,172 Shares of Common Stock of JPMorgan Chase & Co.
Ladies and Gentlemen:
We have acted as counsel to JPMorgan Chase & Co., a Delaware corporation (the “Company”), in connection with the registration under the Securities Act of 1933, as amended (the “Act”), of the proposed offering and sale of up to 1,994,172 shares (the “Shares”) of common stock, $1.00 par value per share, of the Company (“Common Stock”), covered by the Registration Statement on Form S-3 (Reg. No. 333-285537) (the “Registration Statement”) filed by the Company with the Securities and Exchange Commission (the “SEC”) on March 4, 2025, for the proposed offering by the Company of Common Stock through the JPMorgan Chase & Co. Dividend Reinvestment Plan (the “Plan”).
In connection with this opinion letter, we have examined originals, or copies certified or otherwise identified to our satisfaction, of (i) the Registration Statement and the prospectus included therein, (ii) the prospectus supplement dated April 10, 2025, relating to the Shares (the “Prospectus Supplement”), (iii) the Restated Certificate of Incorporation of the Company as amended by the Amendment to the Restated Certificate of Incorporation of the Company effective June 7, 2013, (iv) the By-laws of the Company, as amended, effective September 19, 2023, (v) certain resolutions of the Company’s Board of Directors relating to the registration, sale, and issuance of the Shares and the approval of the Plan, (vi) the Plan, and (vii) such other documents, records, and other instruments as we have deemed appropriated for purposes of the opinion set forth herein.
We have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity with the originals of all documents submitted to us as certified, facsimile, or photostatic copies, and the authenticity of the originals of all documents submitted to us as copies.
Based upon the foregoing, we are of the opinion that the Shares have been duly authorized by the Company and, when issued by the Company and delivered by the Company, in the manner contemplated by the Plan, will be validly issued, fully paid, and non-assessable.
The opinions expressed herein are limited to the laws of the State of Delaware, and we express no opinion with respect to the laws of any other state or jurisdiction. Furthermore, we express no opinion on any matter covered by the “blue sky” or securities laws of any state or foreign jurisdiction.
This opinion letter is effective as of the date hereof. We do not assume responsibility for updating this opinion letter as of any date subsequent to its date, and we assume no responsibility for advising you of any changes with respect to any matters described in this opinion letter that may occur, or facts that may come to our attention, subsequent to the date hereof.
We hereby consent to the filing of this opinion letter with the SEC as an exhibit to a Current Report on Form 8-K to be filed with the SEC (and its incorporation by reference into the Registration Statement) in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Act and to the reference to us under the caption “Legal Opinions” in the Prospectus Supplement. In giving such consent, we do not hereby admit that we are acting within the category of persons whose consent is required under Section 7 of the Act or the rules or regulations of the SEC thereunder. In rendering this opinion letter, we are opining only as to the specific legal issues expressly set forth herein, and no opinion shall be inferred as to any other matter or matters.
Very truly yours,
/s/ Morgan,Lewis & Bockius LLP